Hepatitis B virus (HBV) infection is a global medical concern with huge social and economic impacts. In the current practice, hepatitis B immunoglobulin (HBIG) prepared from pooled serum of immunized donors is prescribed to prevent HBV transmissions, such as mother-to-child transmission, acute exposure, and donor-receptor infection for orthotopic liver transplant patients. As a plasma-derived product, the clinical application of HBIG is limited by serum supply, potential of unknown pathogens and other risk factors in the pooled blood, and up-limits of functional dose. Although recombinant anti-HBV monoclonal antibody is being sorted as a practical alternative for HBIG, its research and development is in a relatively slow pace comparing to the other products. One of the most critical speed-limiting steps is the lack of an established preclinical evaluating system for anti-HBV monoclonal antibodies. Current research progress on functional evaluation of anti-HBV antibodies are reviewed in this paper.